You haven't searched anything yet.
Lycia Therapeutics, Inc. is a biotechnology company leveraging its lysosomal targeting chimera (LYTAC) platform from Founder and Chemistry Nobel Laureate 2022, Carolyn Bertozzi, to discover and develop first-in-class therapeutics that degrade extracellular and membrane-bound proteins. Lycia’s next generation degraders harness the cell’s endogenous lysosomal trafficking and degradation machinery with the potential to degrade targets previously considered to be intractable, across a spectrum of indications. After raising $105 million in capital in 2021, Lycia is advancing an internal pipeline of novel degraders and has entered a strategic collaboration with Eli Lilly to address key unmet medical needs. Lycia is headquartered in South San Francisco.
Visit https://lyciatx.com/ for more information.
The Role:
Lycia Therapeutics is seeking an experienced, motivated, and collaborative Scientist with a background in molecular engineering and a strong background in recombinant protein expression to help us advance our therapeutic platform in protein degradation. The Scientist will join our Biologics department and, as part of the Expression team, will contribute at the front end of our weekly production workflows.
\nKey Responsibilities:
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status
Full Time
$150k-187k (estimate)
03/30/2024
06/27/2024
lyciatx.com
<25